TEDESCHI, ALESSANDRA
 Distribuzione geografica
Continente #
EU - Europa 146
AS - Asia 48
NA - Nord America 48
Totale 242
Nazione #
IT - Italia 116
US - Stati Uniti d'America 47
CN - Cina 26
SG - Singapore 21
DE - Germania 15
CZ - Repubblica Ceca 6
FI - Finlandia 4
GB - Regno Unito 2
RO - Romania 2
IN - India 1
PA - Panama 1
SI - Slovenia 1
Totale 242
Città #
Florence 82
Boardman 25
Singapore 20
Munich 13
Noto 11
Sesto Fiorentino 11
Rome 4
Wuhan 4
Guangzhou 3
Helsinki 3
Ogden 3
Shanghai 3
Bologna 2
Bucharest 2
London 2
New York 2
Pomigliano d'Arco 2
Zibo 2
Beijing 1
Brooklyn 1
Dipignano 1
Falkenstein 1
Jinhua 1
Lappeenranta 1
Ljubljana 1
Miami 1
Panama City 1
Rende 1
Yiwu 1
Totale 205
Nome #
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 30
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 25
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 25
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 25
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 23
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 23
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 21
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 20
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 18
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 17
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 15
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 12
Totale 254
Categoria #
all - tutte 2.836
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.836


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202342 0 0 0 0 0 0 20 3 4 2 10 3
2023/2024132 1 2 27 38 11 14 11 5 4 1 1 17
2024/202580 17 24 0 13 26 0 0 0 0 0 0 0
Totale 254